Posted: February 23, 2019
In this first episode, Jeff Pike is joined by Collin Watson. Collin recently graduated with a dual MBA/MHA, and is in the middle of a leadership rotational program in the pharmaceutical industry. They cover an awesome variety of topics including Collin’s educational background & work experience, his passion for drug development, some of the work he has done already in strategy and marketing, current healthcare policy trends, and his key words of advice for future pharma professionals.
Posted: November 07, 2018
MSL Professional Jamie M. Dettler-Leonard, PhD, BCMAS from Johnson & Johnson discusses her experience with the BCMAS program on the Pharmacy Podcast Network.
Posted: June 28, 2018
According to the Edelman survey on trust, 77% of people surveyed refused to purchase a product or service because they did not trust the company behind it. Pharma companies are not exactly tops on the trust scale for reasons you can infer yourself—or listen to EP148 with Jennifer Miller on the Good Pharma Scorecard. As with most…Read More
Posted: June 21, 2018
An experienced executive with several years of experience in the pharmaceutical and biotechnology industry, Dr. Soliman has held key positions within medical affairs where he was instrumental in launching a variety of innovative platforms expanding the role of medical affairs across the industry.
Posted: December, 2019
ACMA has forged a strategic partnership with Medical Affairs Canada (MAC) to advance the training for Medical Affairs professionals and to offer the Board-Certified Medical Affairs Specialist (BCMAS) designation with content that is consistent with the Canadian marketplace.
Posted: May, 2019
Christine Megalla, Pharm.D., Associate Director of Educational Programs at the Accreditation Council for Medical Affairs, talks about the organization’s certification process.
Posted: Sept 06, 2018
The ACMA has appointed Dr. Charles Stacey, President and CEO of Accera Pharmaceuticals to its Board of Governors. Dr. Stacey is the President and CEO of Accera, a global clinical stage biotechnology company focused on the development of therapeutics for CNS disease. Prior to joining Accera, he was with Inventages, the Nestlé backed venture capital and private equity group, with $1.5Bn under management. There he led the CNS interest as well as the fund's interest in Asia. Prior to Inventages, Dr. Stacey ran a medical device company and worked for a number of early-stage healthcare companies.
Posted: Aug 30, 2018
The ACMA has appointed two power players to its Board of Governors Bob Oliver and S. Bob Chib.
Bob Oliver, Recent CEO of V ClinBio, former President and CEO of Otsuka Pharmaceuticals, who also serves as Executive Advisor for both Cellix Bio Sciences Inc and Hyalo Technologies, while serving on the Board of Directors for Neurotez Inc., joins the ACMA Board today.
S. Bob Chib, currently serves as the Head of Corporate Strategy, Innovation, and Business Development at Astellas Pharma. Mr. Chib has more than two decades' experience as a senior biopharma executive.
Posted: July 10, 2018
The partnership between the ACMA and Council for Continuing Pharmaceutical Education (CCPE) will enable more medical affairs and MSL professionals in Canada to become Board Certified in Medical Affairs via the Board Certified Medical Affairs Specialist Program (BCMAS). The CCPE and ACMA have collaborated to put together a first in class training program tailored for Canadian MSL professionals.
Posted: November 14, 2018